Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study.
Biotherapy Unit, Institut Curie, Paris, France.
J
J
Michon
S
S
Négrier
C
C
Coze
C
C
Mathiot
D
D
Frappaz
R
R
Oskam
H
H
Pacquement
E
E
Quintana
E
E
Bouffet
J L
JL
Bernard
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D005602:France; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009447:Neuroblastoma / Q000628:therapy*; D011379:Prognosis; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D016019:Survival Analysis; D014182:Transplantation, Autologous
D007376:Interleukin-2; D011994:Recombinant Proteins